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Objective: One of the late-onset complications of cardiac implanted electronic devices
(CIEDs) is central venous obstruction (CVO). The aim of this study was to investigate the
feasibility, efficacy, and safety of endovascular treatment of CIED-related CVOs.
Methods: Eighteen patients who underwent endovascular management of their
device-related CVO were reviewed. Patients were classified into three groups: Group I
patients were asymptomatic and needed lead replacement; Group II patients presented
with symptomatic CVO without lead dysfunction, and Group III patients were referred
with both symptomatic CVO and lead dysfunction. A treatment strategy involved
recanalization and balloon angioplasty for Group I and angioplasty/stents for Groups II
and III. Technical success, clinical success, complications, and long-term follow-up were
assessed.
Results: Thirteen patients were in Group I, four in Group II, and one in Group III. Technical
and clinical success was achieved in 17 patients (94%). No major complications were
reported. Restenosis was observed in two patients at 40 and 42 weeks of follow-up, and
these patients were successfully treated with angioplasty.
Conclusion: Endovascular management of CVO due to CIED is a safe and efficient
technique. Plain balloon angioplasty is sufficient for lead replacement purposes, while
stenting is needed for symptomatic CVO to achieve good long-term patency.
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INTRODUCTION
Since their introduction in 1960s, transvenous cardiac implanted electronic devices (CIED) (which
include pacemakers, cardioverter-defibrillators, and cardiac resynchronization therapies) continue
to provide obvious benefits for the management cardiac rhythm disorders and heart failure
(1). They are, however, associated with such complications as device dislodgement, perforation,
infection, migration, and vein stenosis or thrombosis (2). With the growing number of CIED
implantations, complication prevention, and management are a crucial clinical issue. Central
venous obstruction (CVO) is the most important complication. The reported incidence of CVO
after CIED implantation varies widely (3).
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CVOs are usually asymptomatic (4). It was reported that
only 50% of patients with CVOs are symptomatic (5). The most
severe clinical consequence is the development of superior vena
cava syndrome (SVCS) (5). Fortunately, the incidence of CIED-
induced SVCS is rare (less than 0.1%) (6).
There are various approaches for managing CIED-
induced CVOs, which can be applied as monotherapies or
as combotherapies. Pharmacological or pharmacomechanical
management is preferred in cases of recent thrombosis (7).
Endovascular or surgical treatments are indicated when a CVO
is diagnosed (8).
The technique of endovascular management of benign causes
of SVC syndrome has been described in a previous report (9).
An important issue within this patient population is whether
CIED leads have to be removed before stent placement. Several
studies have demonstrated no early complications related to the
metal-to-metal contact between the lead and stents in vivo (10).
However, there is still a concern about the long-term effects (11).
Furthermore, the patency of access veins is another critical
issue. This is because the incidence of CVOs in patients who are
candidates for CIED is as high as 11% prior to the first device
(12). It is also becausemany patients after CIED implantation will
undergo additional procedures for lead revisions or upgrades.
Currently, future clinical challenges relate to identifying patients
who will benefit from the detection of silent CVOs before CIED
implantation, identifying patients that should have superior vena
cava system assessment before lead revision, and determining
how to manage chronic CVO in symptomatic and asymptomatic
patients with CIED.
The aim of this single-center study was to evaluate the efficacy




We reviewed all patients with history of a CIED, who were
referred to the Radiology department for CVO from February
2005 to April 2016. Patients with hemodialysis arterio-venous
shunts were excluded. Our institutional ethics committee
approved this study. Written consent was obtained from all
patients for each procedure. From this population of patients,
we found 18 patients (13 men and 5 women) who had been
treated with percutaneous endovascular techniques. The mean
age was 69 ± 10 years (range: 48–85 years). Sixteen patients
had a pacemaker, and only two had a defibrillator. Table 1,
demonstrates demographic and clinical information of the
patients. They have been classified into three groups based
on the presence of symptoms and/or CIED dysfunction as
follows:
1) Group I: Patients were asymptomatic, but it was suspected
that they had CVOs due to the failure of pacemaker lead
extraction and/or upgrade or because of a failure to insert a
peripheral central line.
2) Group II: Patients presented with CVO-related symptoms. No
dysfunction of the CIED existed.
3) Group III: Patients were symptomatic, and CIED had to be
changed due to dysfunction.
All patients were evaluated with conventional venography. In
symptomatic patients, direct CT venography (13) was also
performed in order to evaluate collateral supplies and define
jugular drainage. SVCs and CVOs were classified based on the
location and degree of obstruction as follow:
- Type I: There is an isolated stenosis of the SVC;
- Type II: Corresponds to a central vein stenosis with or without
extension to the SVC;
- Type III: A chronic total occlusion of the SVC;
- Type IV: Corresponds to a chronic total occlusion of central
veins with or without extension to the SVC.
Technique Description
Two radiologists with 20 and 25 years of experience in vascular
interventions treated the patients. Before any procedure
venography was performed, the ipsilateral basilic or brachial
vein was punctured under ultrasound guidance, and a 4-French
10-cm introducer sheath was inserted. Based on venography
results, a single or combined venous approach (brachial and
femoral) was used. In asymptomatic patients, hydrophilic
guidewire-based (Terumo European N.V., Leuven, Belgium)
recanalization was performed through the same access (brachial)
or through femoral access in four patients (30%) based on
the radiologist’s preference. A 6-French introducer sheath
was used. After the administration of 5,000 IU of heparin,
angioplasty was performed starting with a small-sized balloon,
and this was gradually upgraded in size. The goal was to
dilate the vein at this level to facilitate passage of new leads or
catheters (Figure 1). Typically, ambulatory patients remained
for 4 hours in the radiology department for monitoring
before discharge. Balloon angioplasty with progressive
dilatation was performed using 4 to 10mm high-pressure
balloons.
In patients with SVC syndrome, the common femoral vein
was punctured, and a 10-French 65-cm introducer sheath was
inserted. Venography was performed via brachial access through
a 4-French introducer sheath or through the 5-French vertebral
curve catheter introduced via femoral access. Recanalization,
pressure measurements, and gradual angioplasty were performed
as described byQanadli et al. (9) and Breault et al. (14) (Figure 2).
Progressive angioplasty was performed using 6 to 14mm high-
pressure balloons. In all patients, SinusXL stents (OptiMed,
Ettlingen, Germany), which varied from 16 to 24mm, were
used because of recoil and residual stenosis (Table 2). In order
to avoid proximal displacement, the stent was under-dilated.
Patients were monitored post-operatively for at least 24 h in
order to manage any eventual heart failure. Oral anticoagulation
treatment was administered for a 6-month period (Syntrom).
Technical success was defined as follows: Group I, successful
recanalization of the obstruction followed by angioplasty;
Group II, reestablishment of venous blood flow to a normal
physiological pattern; Group III, reestablishment of venous
blood flow to a normal physiological pattern and successful
replacement of the lead. Clinical success was defined as follows:
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TABLE 1 | Patient’s demographic and clinical characteristics.
Patient number/
age
Sex CIED type Indication for CIED
placement
Side Type Vein involved Symptoms Comorbidity
1/52 years F Df Ventricular fibrillation L II In, SVC Headache, dyspnea,
pectoral telangiectasia
Systemic lupus erythematosus
2/64 years M Pc Sick sinus syndrome L II In-SVC junction Left arm edema No
3/69 years M Pc Sick sinus syndrome L IV SVC Head and neck edema Hypertension
4/72 years M Pc Atrioventricular block L II SVC Upper body edema COPD
5/76 years M Pc Sick sinus syndrome L IV SVC Upper body edema No
6/68 years M Pc Dilated cardiomyopathy with
heart failure
R IV Sc No Renal insufficiency
7/48 years M Pc Sick sinus syndrome R II Sc, In No Cirrhosis
8/67 years M Pc Bradycardia L IV Sc, In No Hypertension
9/82 years F Pc Syncope L II In-SVC junction No Obesity
10/62 years F Pc Sick sinus syndrome L II Sc No PAD
11/66 years M Pc Ventricular tachycardia L IV In-SVC junction No No
12/85 years M Pc Sick sinus syndrome L II Sc, In No PAD
13/64 years M Pc Atrioventricular block L IV Sc, In No COPD
14/83 years M Df Ventricular tachycardia L II Sc, In No PAD
15/70 years M Pc Bradycardia L IV Sc, In No Renal insufficiency
16/75 years M Pc Sick sinus syndrome R IV Sc, In No No
17/65 years M Pc Syncope L II Sc, In No Cirrhosis
18/78 years M Pc Sick sinus syndrome L IV In-SVC junction No No
Df, Defibrillator; Pc, Pacemaker; In, Innominate vein; Sc, Subclavian vein; SVC, Superior Vena Cava; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease.
FIGURE 1 | A 70-year-old asymptomatic man (Group I) living with a pacemaker for 3 years was candidate for lead replacement due to dysfunction. Venography was
considered because of failure to advance new leads in the Cath-Lab. (A) Venography revealed occlusion of the left innominate vein with the presence of collateral
veins. (B) Left innominate vein angioplasty was performed in order to facilitate lead passage.
Group II and III, regression or resolution of symptoms 48 h to 1
week after treatment. All symptomatic patients were followed up
clinically with CT venography and a systematic visit at 3 months
as a standard care workflow. A telephone contact was maintained
for a long-term follow evaluation for all groups of patients.
RESULTS
We identified 13 patients in Group I, four in group II, and one in
group III. From Group II, one patient presented with swelling
of the face and shortness of breath, one with swelling of the
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FIGURE 2 | 52-year-old woman with a defibrillator for the past 5 years presented with headache and dyspnea for 20 months. No dysfunction of the CIED was noted
(Group II). (A) Cavography of the SVC was performed, revealing severe stenosis of the SVC. (B) CT images of MIP coronal reconstruction, showing fibrotic stenosis of
the left innominate vein. (C,D) Progressive balloon angioplasty and stenting of the SVC was performed without lead removal. (E) Cavography showed normal flow
through the stent. The patient’s symptoms disappeared completely 3 days later.
TABLE 2 | Details of material and complications in symptomatic patients.
Patient number/age Sex Ballon size in mm Sinus XL stent size in mm Intrastent symptomatic restenosis Complication
1/52 years F 6, 8, 10 20 In 40 weeks No
2/64 years M 10, 12 22 No No
3/69 years M 8, 10 16 In 42 weeks No
4/72 years M 12, 14 24 No No
5/76 years M 8, 10 20 No Early battery discharge
left arm, one with swelling of the face and neck accompanied
by hoarseness, and one with swelling of the upper body. The
patient in Group III presented with swelling of the upper body.
Nine patients had Type II obstruction, and nine had Type
IV obstruction. For symptomatic patients, three had Type II
obstruction and two Type IV (Table 1). Asymptomatic patients
were managed only by balloon angioplasty, while symptomatic
patients received angioplasty and stent placement. In one
asymptomatic patient with Type II obstruction, recanalization
failed.
In asymptomatic patients, hydrophilic guidewire-based
recanalization was performed through the same access (brachial)
in seven patients (54%) and through the femoral access in five
patients (38%). In one patient, both femoral and brachial access
were needed. The subclavian vein was involved in 10 patients, the
innominate vein in 10 patients, and the innominate vein-SVC
junction in three patients.
Symptomatic patients were treated using the femoral venous
approach. A brachial access was used to perform initial
venography and a subsequent control series. The innominate
vein-SVC junction was involved in one patient, and the SVC
was involved in four patients. High pressure and short balloons
were preferred over long balloons to provide spot or multiple
angioplasties (if required). The deflation time was usually very
long for large-diameter high-pressure balloons, which is often
less tolerated by patients. We also believe that the theoretical risk
of rupture might be increased with long balloons aiming to dilate
the innominate vein and the SVC simultaneously. A sinus XL
stent was used in all patients with a nominal diameter. In-stent
remodeling with balloons was systematic. Patients in Group III
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were treated initially with balloon angioplasty and stenting over
the ancient leads. The leads were not removed, and the new leads
were inserted through the stent to the cardiac cavities.
Stenosis at the entry site with proximal extension was more
often present in patients (56%). Obstructions located only at the
insertion site were found in two patients (11%), and obstructions
located distal to the insertion point were present in six patients
(33%). Symptoms were present when stenosis involved the SVC
or the innominate vein-SVC junction.
Technical and clinical success was achieved in 17 of 18 patients
(94%).
No early complications were observed. In one symptomatic
patient treated with a stent, the battery had to be replaced 2 years
sooner than expected.
At 3 months of follow-up, all patients were asymptomatic,
and in Groups II and III CTs showed stent patency without
early stenosis. In one patient from Group I, the electrodes of
the pacemaker had to be changed 4 years later, and cardiologists
had difficulty advancing new leads through the central veins.
Venography revealed subclavian vein restenosis, which was
successfully treated with angioplasty.
Two of the symptomatic patients presented with symptom
recurrence at 40 and 42 weeks of follow-up, and they were
retreated successfully with angioplasty (Figure 3). All patients
have experienced no further symptoms as of today (37 ± 27
months of follow-up), which has been verified by telephone
communication.
DISCUSSION
Our data showed that 70% of patients were asymptomatic, while
about half of all CVOs were total occlusions. Symptoms seemed
to be more related to obstruction extension than to obstruction
degree. In the literature, CVOwas observed in 14–64% of patients
after pacemaker insertion (15). Total occlusions were reported
in up to 26% of patients (16). More than 75% of CVOs were
observed after 6 months (17).
The mechanism underpinning the development of a CVO
after lead placement has been debated and is not fully understood.
Endothelial disruption due to mechanical stress or infection
of leads is the main factor thought to predispose a patient to
developing a CVO (18). Induced inflammatory changes in the
vessel wall with subsequent scarring and fibrosis might lead to
progressive vessel wall and lumen remodeling resulting in vessel
lumen reduction (19–22). Furthermore, thrombus formation
might also play a significant role. Lonyai et al. presented a
novel application of computational methods to study blood flow
changes induced by pacemaker leads (23). Their results showed
that lead placement could result in pockets of low blood flow
velocities between leads and vessel walls, predisposing patients to
FIGURE 3 | A 75-year-old man living with a pacemaker for the past 4 years complained of headache and facial edema for the last 3 months. No dysfunction of his
pacemaker was found (Group II). (A,B) Initial venography showed severe stenosis of the SVC, which was successfully treated by angioplasty and stenting. After 40
months, the patient presented again with the same symptoms. (C–E) Radiological evaluation demonstrated stenosis in the SVC stent, which was successfully treated
by angioplasty.
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vein thrombosis. The reported risk factors of CIED-related CVO
include a history of device upgrade, the presence of temporary
endocardial pacemaker wires before permanent implantation,
lead infection, the use of dual-coil leads, hormone therapy, and
a history of venous thrombosis (24). The number of leads may
also contribute to this condition (19, 20). Narrowing of the
vessel due to the presence of more leads and endothelial damage
due to physical manipulation may make the vein susceptible to
thrombosis and fibrotic scarring (25). Female gender (26) and
diabetes (27) have a protective effect against the development of
CVO.
The fibrotic changes in the vein wall might impact
endovascular management because these changes are often
responsible for the elastic recoil observed after angioplasty. In
order tomaintain vessel recoil, gradual balloon angioplasty under
high pressure is required. The recoil is sometimes so important
that even after appropriate angioplasty, the insertion of newwires
is not feasible. In that case, when angioplasty has been performed,
a 6-French long introducer (25 cm) is used with its tip placed
distal to the obstruction. Afterwards, leads can be advanced in the
cardiac cavities through this introducer.When leads are placed in
the suitable position, then the introducer is removed.
Angioplasty or stenting was well-tolerated by our patients.
No heart failure was noted after treatment in symptomatic
patients. All patients experienced improvements in symptoms
immediately after endovascular treatment. Undoubtedly,
endovascular treatment may potentially be associated with lead
damage. Progressive angioplasty is critical in order to avoid this
potential complication. In cases of endovascular stent placement
over pacemaker wires, one possible concern is the long-term
effect on pacemaker function resulting from metal-to-metal
contact (10, 28, 29). Isolation between the wires and the stent
does exist when pacemaker leads are covered by polyurethane
and by a layer of neointimal endothelialization along segments
fully opposed to the vein wall. However, at points where there
is no contact with the vein wall or after stress post-angioplasty,
isolation may fail. Thus, a potential risk for dysfunction exists.
In our five patients treated with stenting of the SVC without
lead removal, one presented with early battery dysfunction. One
patient was treated 7 years before, and no dysfunction of his
pacemaker has been noted over this relatively long time period.
These findings are consistent with those from the retrospective
review of Riley et al. for the management of retained leads, which
reported no adverse effects after stenting (8).
In our study, we did not try to extract wires before
endovascular angioplasty in symptomatic patients. One option is
lead extraction assisted with a laser method before angioplasty
and stenting in order to avoid recurrence. However, this
technique has important risks (22, 30, 31) and higher costs.
Moreover, lead retention was not associated with symptom
recurrence (8).
In symptomatic patients, venous bypass followed by surgical
thrombectomy is a theoretical alternative treatment, albeit
a highly invasive operation with a higher recurrence rate
than percutaneous methods (8). Other alternatives include
contralateral implantation of a completely new system,
recanalization using laser tools, gaining access medially to
the occlusion, femoral/iliac access with a femoral/abdominal
pocket, and epicardial lead placement (32, 33). We do not
recommend contralateral insertion, particularly in asymptomatic
patients. This is because the risk of developing symptoms is high.
A promising emerging method to treat cardiac rhythm disorders
could be the use of leadless devices that have the advantage of
less risk of CVO (34, 35).
The present study has two primary limitations: (1) the small
number of patients and (2) the retrospective collection of data.
Moreover, all symptomatic patients were treated using a Sinus
XL stent. As a result, we have no experience with metal-to-metal
interactions between pacemaker leads and other types of venous
stents.
In conclusion, endovascular management of induced CVOs
is a safe and efficient technique. Plain balloon angioplasty is
sufficient for lead replacement purposes, while stenting is feasible
and safe for symptomatic CVOs, resulting in good clinical
outcomes.
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